What is MeMed?
MeMed operates at the intersection of immunology and data science, specializing in the translation of complex immune system signals into actionable clinical insights. The company's core technology utilizes sophisticated machine-learning algorithms to analyze host-response profiles, effectively distinguishing between bacterial and viral infections. This capability addresses critical clinical dilemmas, such as the over-prescription of antibiotics, by providing rapid, accurate diagnostic data. By focusing on host-response rather than pathogen detection, MeMed offers a unique value proposition that enhances patient outcomes and optimizes hospital resource allocation. The company's portfolio is designed to scale across diverse healthcare environments, reflecting a robust commitment to evidence-based medical innovation.
How much funding has MeMed raised?
MeMed has raised a total of $93M across 1 funding round:
Private Equity
$93M
Private Equity (2022): $93M with participation from Shavit Capital, La Maison Partners, Social Capital, and Horizons Ventures
Key Investors in MeMed
Shavit Capital
Shavit Capital is an investment practice specializing in late-stage financing for Israeli-related companies, focusing on firms with proven technologies and strong management teams.
La Maison Partners
La Maison Partners is an entrepreneurial investment firm that supports high-growth companies through venture capital and LBO strategies, aiming to build future industry champions.
Horizons Ventures
Horizons Ventures focuses on deep science and technology investments, targeting transformative projects that aim to advance humanity and improve global standards.
What's next for MeMed?
With this major strategic investment, MeMed is well-positioned to scale its diagnostic infrastructure and expand its global footprint. The company is expected to prioritize the regulatory clearance and commercial rollout of its flagship tests, while simultaneously deepening its R&D pipeline to address additional infectious disease markers. As the healthcare sector increasingly shifts toward personalized diagnostics, MeMed's ability to provide rapid, high-fidelity insights will be instrumental in driving clinical adoption. Future growth will likely focus on strategic partnerships with major hospital networks and diagnostic laboratories, ensuring that their immune-profiling technology becomes a standard of care in acute clinical settings.
See full MeMed company page
